Trial Profile
A Phase 2, Open-Label, Single-Arm Study of Cabozantinib in Japanese Patients With Advanced Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary)
- Indications Renal cell carcinoma
- Focus Registrational; Therapeutic Use
- Sponsors Takeda
- 02 Oct 2020 Status changed from active, no longer recruiting to completed.
- 31 May 2020 Results of post-hoc pooled analysis of patients who had received prior IO therapy from METEOR and C2001 presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 25 Mar 2020 According to an Exelixis media release, the company announced that Takeda Pharmaceutical Company Limited (Takeda) has received approval from the Japanese Ministry of Health, Labor and Welfare to manufacture and market CABOMETYX as a treatment for patients with curatively unresectable or metastatic renal cell carcinoma (RCC). The approval is based on the results of three clinical trials: METEOR, CABOSUN and Cabozantinib-2001.